Pronounce: Nye-vol'-ue-mab and Rel-at-li-mab
Classification: Programmed death receptor-1 (PD-1) blocking antibody (nivolumab) and a lymphocyte activation gene-3 (LAG-3) blocking antibody (relatlimab).
This medication is a combination of the programmed death receptor-1 (PD-1) blocking antibody nivolumab and the LAG-3-blocking antibody relatlimab. It is used for some types of skin cancer.
The immune system works by creating antibodies, which are proteins that attach to the surface of a cell. The antibody “calls” the immune system to attack the cell it is attached to, causing the immune system to kill the cell. Monoclonal antibodies are made in a lab to attach to certain types of cancer cells. These antibodies can work in different ways, including stimulating (revving up) the immune system to kill the cell, blocking cell growth, or other things needed for cell growth. Nivolumab and relatlimab are both monoclonal antibodies.
Targeting LAG3 along with PD1 may help restore T-cells and can help with an anti-tumor immune response.
Nivolumab and relatlimab-rmbw is given by a single intravenous (IV, into a vein) infusion (both medications are mixed together and given at the same time). The dose and how often you receive the medication will be decided by your care team.
Make sure your care team is aware of all medications (including prescription and over-the-counter), supplements, and vitamins you are taking. Steroids should be avoided while on immunotherapy unless directed by your care team.
Tell your care team about all your medical conditions, including those that are autoimmune in nature (Crohn’s disease, lupus, rheumatoid arthritis, etc.) as these can get worse with immunotherapy. You should also notify your provider if you have had or plan on having an allogeneic stem cell transplant as this medication can worsen a side effect of the transplant called graft-versus-host disease.
There are a number of things you can do to manage the side effects of nivolumab. Talk to your care team about these recommendations. They can help you decide what will work best for you. These are some of the most common or important side effects:
Your healthcare provider can recommend medications and other strategies to help relieve pain.
Fatigue is very common during cancer treatment and is an overwhelming feeling of exhaustion that is not usually relieved by rest. While on cancer treatment, and for a period after, you may need to adjust your schedule to manage fatigue. Plan times to rest during the day and conserve energy for more important activities. Exercise can help combat fatigue; a simple daily walk with a friend can help. Talk to your healthcare team for helpful tips on dealing with this side effect.
Your red blood cells are responsible for carrying oxygen to the tissues in your body. When the red cell count is low, you may feel tired or weak. You should let your oncology care team know if you experience any shortness of breath, difficulty breathing or pain in your chest. If the count gets too low, you may receive a blood transfusion.
White blood cells (WBC) are important for fighting infection. A lymphocyte is one kind of white blood cell. While receiving treatment, your WBC count can drop, putting you at a higher risk of getting an infection. You should let your care team know right away if you have a fever (temperature greater than 100.4°F or 38°C), sore throat or cold, shortness of breath, cough, burning with urination, or a sore that doesn't heal.
Tips for preventing infection:
Some patients may develop a rash, scaly skin, or red itchy bumps. Use an alcohol-free moisturizer on your skin and lips; avoid moisturizers with perfumes or scents. Your oncology care team can recommend a topical medication if itching is bothersome. If your skin does crack or bleed, be sure to keep the area clean to avoid infection. Be sure to notify your oncology care team of any rash that develops, as this can be a reaction. They can give you more tips on caring for your skin.
This medication can affect the level of sodium (and possibly other electrolytes) in your body. Your levels will be monitored using blood tests. If your levels become too low, your care team may prescribe specific electrolytes to be given by IV or taken by mouth. Do not take any supplements without first consulting with your care team.
Exposure of an unborn child to this medication could cause birth defects, so women should not become pregnant while on this medication. Even if your menstrual cycle stops, effective birth control is necessary during treatment and for 5 months after stopping treatment. Men should ask their provider about contraception needs. You should not breastfeed while taking this medication or for 5 months after the end of treatment.
OncoLink is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through OncoLink should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem or have questions or concerns about the medication that you have been prescribed, you should consult your health care provider.
Information Provided By: www.oncolink.org | © 2025 Trustees of The University of Pennsylvania